What Lexaria Bioscience does

Lexaria Bioscience Corp. (NASDAQ:LEXX) is a clinical-stage biotechnology company that develops and out-licenses its proprietary DehydraTECH drug delivery platform. DehydraTECH is a patented process that mixes active pharmaceutical ingredients (APIs) with fatty acid-rich triglyceride oils and infuses the mixture into substrate materials via controlled dehydration synthesis, enabling molecular association of payload and oils. The technology is applicable to small and large molecule therapeutics (including GLP-1 peptides), works across tablets, capsules, oral suspensions, and consumable liquids, supports both hepatic and lymphatic transport pathways, masks taste and odor, and has demonstrated blood-brain barrier penetration. The platform is protected by 65 granted patents across the US, Australia, EU, Japan, Mexico, Canada, and India, with additional applications pending.

The company monetizes DehydraTECH through three revenue streams: (1) technology licensing to pharmaceutical, nutraceutical, and consumer product companies via up-front fees, milestone payments, and royalties; (2) toll processing of GMP-grade intermediate formulations for corporate clients; and (3) contract research and formulation services, including CRO contracts and Material Transfer Agreements with pharmaceutical partners evaluating DehydraTECH with specific APIs. Named enterprise relationships include Altria (smokeless nicotine), Novo Nordisk (semaglutide/amycretin evaluation), an unnamed PharmaCO under an MTA extended through December 2026 with a temporary exclusive license in GLP-1, plus consumer-facing licensees Nic's Beverages and Amari Corp.

Lexaria is incorporated in Nevada, headquartered in Kelowna, BC (Canada), with US operations in Tyrone, GA, and operates through five wholly-owned subsidiaries (Lexaria Pharmaceutical Corp., Lexaria Nicotine LLC, Lexaria Hemp Corp., Lexaria Canpharm ULC, Lexaria Nutraceutical Corp.) plus patent-holding Poviva Corp. Recent clinical milestones include the December 2025 Phase 1b GLP-1-H24-4 primary endpoint readout showing 48% lower overall side effects versus Rybelsus, alongside granted patents covering diabetes, hypertension, antivirals, epilepsy, and sublingual nicotine delivery.

Name

Lexaria Bioscience

Legal name

Lexaria Bioscience Corp.

Website

https://lexariabioscience.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Lexaria Bioscience Corp. (NASDAQ:LEXX) is a clinical-stage biotechnology company that develops and out-licenses its proprietary DehydraTECH drug delivery platform, which improves oral bioavailability of active pharmaceutical ingredients for pharmaceutical, nutraceutical, and consumer product partners worldwide.

Ownership category

akta.pro rank

Product category

Drug Delivery Technology

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Hydrocolloid Stabilizers (Xanthan, Guar, Locust Bean, Carrageenan, Alginate, Pectin, Cellulose) (AFAJACAF)

akta.pro secondary industry

Beverage Emulsions & Clouding Agents (Flavor Emulsions, Weighting Agents) (AFAJACAK)

Keywords

• Drug delivery platform
• Oral bioavailability technology
• Pharmaceutical technology licensing
• GLP-1 formulation
• CBD absorption technology

Headquarters

HQ city

Kelowna

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Technology Licensing: Lexaria out-licenses its DehydraTECH technology to pharmaceutical, nutraceutical, and consumer product companies in exchange for up-front fees, milestone payments, and/or royalty payments. Licensing covers the delivery of fat-soluble active molecules and drugs.
2. Toll Processing: Lexaria offers dietary supplement GMP-grade intermediate formulations to corporate clients on a toll processing basis, providing manufacturing/processing services for DehydraTECH-enhanced products.
3. Research and Development Services: Lexaria conducts contract research and formulation development services for pharmaceutical partners, including CRO contracts for GLP-1 studies and material transfer agreements (MTAs) with pharmaceutical companies evaluating DehydraTECH.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Lexaria Bioscience develops and out-licenses its proprietary DehydraTECH drug delivery platform technology, which enhances oral absorption of fat-soluble active pharmaceutical ingredients (APIs) and bioactive compounds. The technology uses fatty acid-rich triglyceride oils and controlled dehydration synthesis to associate payloads at a molecular level, enabling improved bioavailability, taste/odor masking, blood-brain barrier crossing, and reduced gastrointestinal side effects. Lexaria monetizes DehydraTECH through licensing deals, contract research, and toll processing services to pharmaceutical, biotech, and consumer product companies worldwide.

Product overview

Lexaria Bioscience Corp. is a biotechnology company offering its proprietary DehydraTECH drug delivery platform technology, which improves oral absorption of APIs. The core offering is DehydraTECH, available in versions including DehydraTECH 2.0 for enhanced performance. The company operates five subsidiaries: Lexaria Pharmaceutical Corp. (pharmaceuticals for hypertension, antivirals, epilepsy), Lexaria Nicotine LLC (oral nicotine products), Lexaria Hemp Corp. (hemp B2B), Lexaria Canpharm ULC (Health Canada licensed lab), and Lexaria Nutraceutical Corp. (consumer goods). Key product applications include DehydraTECH-CBD for hypertension, DehydraTECH-GLP-1 for diabetes/weight loss, and DehydraTECH-Nicotine for oral delivery. The company licenses its technology to pharmaceutical and consumer product companies worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• DehydraTECH: Proprietary drug delivery-enabling technology that improves the absorption of active pharmaceutical ingredients into the bloodstream, allowing greater drug effectiveness often with reduced side effects.
• DehydraTECH 2.0
• DehydraTECH-CBD
• TurboCBD

Products and services

• DehydraTECH Patented drug delivery platform technology that improves oral absorption of APIs into the bloodstream by mixing payloads with fatty acid-rich triglyceride oils and using controlled dehydration synthesis. Applicable to small and large molecule therapeutics in tablets, capsules, oral suspensions, and consumable liquids. Licensed to pharmaceutical, nutraceutical, and consumer product companies.
• DehydraTECH 2.0 Enhanced second-generation formulation of DehydraTECH demonstrating up to 2,708% more CBD delivery into bloodstream compared to MCT control formulations in animal studies.
• DehydraTECH-CBD CBD formulations processed with DehydraTECH for potential treatment of hypertension, heart disease, and seizure disorders. Demonstrated up to 23% blood pressure reduction in human clinical studies.
• DehydraTECH-GLP-1 GLP-1 drug formulations (semaglutide, tirzepatide, liraglutide) enhanced with DehydraTECH to enable oral delivery and reduce gastrointestinal side effects compared to injectable formulations. DehydraTECH-semaglutide reduced overall side effects by 48% compared to Rybelsus.
• DehydraTECH-Nicotine Oral nicotine formulations using DehydraTECH technology for faster blood absorption (10x to 20x faster than controls) and improved delivery compared to conventional oral nicotine products, including oral pouches and sublingual delivery.
• Toll Processing Services GMP-grade intermediate formulations provided to corporate clients on a toll processing basis for DehydraTECH-enhanced dietary supplements and consumer products.
• Contract Research and Formulation Development Services Research partnerships and CRO contracts for pharmaceutical partners evaluating DehydraTECH, including Material Transfer Agreements (MTAs) and pre-clinical/clinical study services for GLP-1, antiviral, and other applications.

Quantifiable outcome

• DehydraTECH-semaglutide reduced overall side effects by 48% compared to Rybelsus; gastrointestinal side effects reduced by 55%
• +7 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Five partnerships are on record, tiered core and minor.

• PharmaCO (Unnamed Pharmaceutical Company)coreStrategic or Co-development Partner · 4 September 2024Material Transfer Agreement (MTA) with an unnamed pharmaceutical company (referred to as 'PharmaCO') to evaluate DehydraTECH drug delivery technology for GLP-1 applications in a pre-clinical setting. The agreement was originally entered September 4, 2024 and extended through December 31, 2026. The extension maintains a temporary exclusive license and enables continued strategic planning discussions between the parties. Three GLP-1 studies are ongoing under this arrangement.
• AltriacoreOEM/ Whitelabel/ Licensing PartnerLicensing agreement with Altria for the development of smokeless, oral-based nicotine products using DehydraTECH technology. Lexaria provides DehydraTECH powder-based nicotine formulations to be evaluated by Altria under agreements effective until March 31, 2023.
• Nic's BeveragesminorOEM/ Whitelabel/ Licensing PartnerLicensed DehydraTECH technology to Nic's Beverages (owners of Nic's Cold Brew brand) for use in CBD beverages. Lexaria prepared proprietary DehydraTECH-powered CBD nanoemulsions for the company, demonstrating 93.4% potency retention after one year.
• Amari Corp.minorOEM/ Whitelabel/ Licensing PartnerAmari Corp. uses DehydraTECH technology in their 'Everyday Calm' CBD product, which was named a Top CBD Product Pick by New Hope Network (host of Natural Products Expo).
• Unnamed Multinational Pharmaceutical Companies (Multiple)minorStrategic or Co-development PartnerLexaria is in early-stage discussions with several multinational pharmaceutical companies regarding its oral GLP-1 drug delivery technology. These discussions are aimed at exploring potential licensing or partnership agreements for DehydraTECH in the GLP-1 space.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• IntelGenx Technologies: Oral drug delivery platform company developing thin-film and other proprietary oral formulation technologies for pharmaceutical partners. Directly comparable as a small-cap oral drug delivery licensor pursuing pharma partnerships and reformulation opportunities.
• Aprecia Pharmaceuticals: Pharmaceutical company built around a proprietary 3D-printing oral dosage form technology (ZipDose) for enhanced drug delivery. Comparable as a technology-licensing pharma focused on novel oral administration of established molecules.
• Oramed Pharmaceuticals: Clinical-stage pharma developing an oral delivery platform (Protein Oral Delivery, POD) for peptides and proteins, including oral insulin and oral GLP-1. Directly comparable as a small-cap oral peptide delivery company pursuing pharma licensing.
• Emisphere Technologies: Pioneer in oral drug delivery using the Eligen carrier technology to enable absorption of macromolecules. Closely comparable to Lexaria as an oral bioavailability platform licensor to large pharma partners.
• BioDelivery Sciences International: Specialty pharma built on proprietary drug delivery technologies (e.g., BEMA, BioErodible MucoAdhesive) for pain and addiction therapies. Comparable as a delivery-platform-driven pharma pursuing both in-house and partner products.
• Enteris BioPharma: Clinical-stage oral peptide delivery company offering Peptelligence and ProPerma formulation technologies and contract manufacturing. Comparable to Lexaria for its focus on oral peptide/GLP-1 reformulation and pharma partnership model.
• CURE Pharmaceutical: Drug delivery company developing the CUREform platform for oral thin-film and multi-layer tablets with improved bioavailability. Comparable as a small-cap proprietary oral delivery technology licensor.

Broad incumbents

• Catalent: Large global drug delivery and contract development/manufacturing organization offering a wide range of bioavailability-enhancing formulation services across multiple modalities. Comparable as an incumbent oral bioavailability and drug delivery partner, though at much greater scale and breadth than Lexaria.
• Lonza Group: Global contract development and manufacturing organization serving pharma and biotech with drug substance, drug product, and specialized delivery capabilities including oral bioavailability. Comparable as a broad incumbent in pharma drug delivery services that Lexaria competes against for partner attention.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/lexariacorp
• LinkedInlinkedin.com/company/lexaria-bioscience

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries6 records

Funding overview

Funding rounds10 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lexaria Bioscience